Related references
Note: Only part of the references are listed.A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin
Naris Nilubol et al.
CLINICAL ENDOCRINOLOGY (2017)
Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial
Marcia S. Brose et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases
Shweta Kotian et al.
CLINICAL CANCER RESEARCH (2017)
IL-12 immunotherapy of BrafV600E-induced papillary thyroid cancer in a mouse model
Ranjit S. Parhar et al.
LABORATORY INVESTIGATION (2016)
Histone Deacetylase Inhibitors: A Novel Therapeutic Weapon Against Medullary Thyroid Cancer?
Christos Damaskos et al.
ANTICANCER RESEARCH (2016)
Cancer immunotherapy: the beginning of the end of cancer?
Sofia Farkona et al.
BMC MEDICINE (2016)
Genomic Landscape of poorly Differentiated and Anaplastic Thyroid Carcinoma
Bin Xu et al.
ENDOCRINE PATHOLOGY (2016)
Treatment of advanced thyroid cancer with targeted therapies: ten years of experience
David Viola et al.
ENDOCRINE-RELATED CANCER (2016)
Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer
Jill J. Bastman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers
Inigo Lancia et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial
Marcia S. Brose et al.
LANCET ONCOLOGY (2016)
Evolving molecularly targeted therapies for advanced-stage thyroid cancers
Keith C. Bible et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Danny N. Khalil et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
Bryan R. Haugen et al.
THYROID (2016)
Valproic Acid, a Histone Deacetylase Inhibitor, in Combination with Paclitaxel for Anaplastic Thyroid Cancer: Results of a Multicenter Randomized Controlled Phase II/III Trial
Maria Graziella Catalano et al.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (2016)
Proteomics of thyroid tumours provides new insights into their molecular composition and changes associated with malignancy
Juan Martinez-Aguilar et al.
SCIENTIFIC REPORTS (2016)
Targeted therapies in thyroid cancer: an extensive review of the literature
Athanasios Bikas et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2016)
Management of advanced medullary thyroid cancer
Julien Hadoux et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Anaplastic Thyroid Carcinoma: Treatment in the Age of Molecular Targeted Therapy
Maria E. Cabanillas et al.
JOURNAL OF ONCOLOGY PRACTICE (2016)
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Suzanne L. Topalian et al.
NATURE REVIEWS CANCER (2016)
Regulatory circuits of T cell function in cancer
Daniel E. Speiser et al.
NATURE REVIEWS IMMUNOLOGY (2016)
HER2 Analysis in Sporadic Thyroid Cancer of Follicular Cell Origin
Rosaria M. Ruggeri et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
A Detailed Clinicopathologic Study of ALK-translocated Papillary Thyroid Carcinoma
Angela Chou et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2015)
Targeted therapies in advanced differentiated thyroid cancer
Raquel M. Carneiro et al.
CANCER TREATMENT REVIEWS (2015)
An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer
Sun Min Lim et al.
EUROPEAN JOURNAL OF CANCER (2015)
Remarkable Response to Crizotinib in Woman With Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma
Yann Godbert et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Thibault Voron et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8-Akt-Slug pathway
C. Visciano et al.
ONCOGENE (2015)
BRAF Inhibitor Dabrafenib in Patients with Metastatic BRAF-Mutant Thyroid Cancer
Gerald S. Falchook et al.
THYROID (2015)
PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer
Jill J. Severson et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib
S. Michael Rothenberg et al.
CLINICAL CANCER RESEARCH (2015)
Integrated Genomic Characterization of Papillary Thyroid Carcinoma
Nishant Agrawal et al.
CELL (2014)
MHC Class I Loss Is a Frequent Mechanism of Immune Escape in Papillary Thyroid Cancer That Is Reversed by Interferon and Selumetinib Treatment In Vitro
Trevor E. Angell et al.
CLINICAL CANCER RESEARCH (2014)
Human Anaplastic Thyroid Carcinoma Cells Are Sensitive to NK Cell-Mediated Lysis via ULBP2/5/6 and Chemoattract NK Cells
Erik Wennerberg et al.
CLINICAL CANCER RESEARCH (2014)
New therapeutic options for advanced forms of thyroid cancer
Victor Bernet et al.
EXPERT OPINION ON EMERGING DRUGS (2014)
Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity
Mei-Ling Chen et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Switch in Signaling Control of mTORC1 Activity After Oncoprotein Expression in Thyroid Cancer Cell Lines
Roberta Malaguarnera et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Phosphoproteomics of MAPK Inhibition in BRAF-Mutated Cells and a Role for the Lethal Synergism of Dual BRAF and CK2 Inhibition
Robert Parker et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer
Lindsey M. Kelly et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
BRAFV600E in Papillary Thyroid Carcinoma Is Associated with Increased Programmed Death Ligand 1 Expression and Suppressive Immune Cell Infiltration
Trevor E. Angell et al.
THYROID (2014)
CD8+TIL Recruitment May Revert the Association of MAGE A3 with Aggressive Features in Thyroid Tumors
Mariana Bonjiorno Martins et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2014)
Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets
Christine Spitzweg et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma
Roniel Cabrera et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer
Magali Terme et al.
CANCER RESEARCH (2013)
Frequent Somatic TERT Promoter Mutations in Thyroid Cancer: Higher Prevalence in Advanced Forms of the Disease
Inigo Landa et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
Stephanie M. Pyonteck et al.
NATURE MEDICINE (2013)
Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
Alan L. Ho et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Genetic and Pharmacological Targeting of CSF-1/CSF-1R Inhibits Tumor-Associated Macrophages and Impairs BRAF-Induced Thyroid Cancer Progression
Mabel Ryder et al.
PLOS ONE (2013)
Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF-Mutant Thyroid Carcinomas
Cristina Montero-Conde et al.
CANCER DISCOVERY (2013)
The Expression of Tumor-Associated Macrophages in Papillary Thyroid Carcinoma
Seunghwan Kim et al.
ENDOCRINOLOGY AND METABOLISM (2013)
Global tyrosine kinome profiling of human thyroid tumors identifies Src as a promising target for invasive cancers
Nancy L. Cho et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
Receptor tyrosine kinases in cancer escape from BRAF inhibitors
Roger S. Lo
CELL RESEARCH (2012)
Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements
D. Neil Hayes et al.
CLINICAL CANCER RESEARCH (2012)
Infiltration of a mixture of immune cells may be related to good prognosis in patients with differentiated thyroid carcinoma
Lucas L. Cunha et al.
CLINICAL ENDOCRINOLOGY (2012)
The mTOR Signalling Pathway in Human Cancer
Helena Populo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2012)
Phenotypical Analysis of Lymphocytes with Suppressive and Regulatory Properties (Tregs) and NK Cells in the Papillary Carcinoma of Thyroid
Foteini Gogali et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Programmed Death-1+ T Cells and Regulatory T Cells Are Enriched in Tumor-Involved Lymph Nodes and Associated with Aggressive Features in Papillary Thyroid Cancer
Jena D. French et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Novel Process of Intrathymic Tumor-Immune Tolerance through CCR2-Mediated Recruitment of Sirpα+ Dendritic Cells: A Murine Model
Tomohisa Baba et al.
PLOS ONE (2012)
The sodium iodide symporter (NIS): Regulation and approaches to targeting for cancer therapeutics
Takahiko Kogai et al.
PHARMACOLOGY & THERAPEUTICS (2012)
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
Stephen B. Willingham et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Density of Tumor-Associated Macrophages Correlates with Lymph Node Metastasis in Papillary Thyroid Carcinoma
Wei Qing et al.
THYROID (2012)
Controlling escape from angiogenesis inhibitors
Barbara Sennino et al.
NATURE REVIEWS CANCER (2012)
Anaplastic Thyroid Cancers Harbor Novel Oncogenic Mutations of the ALK Gene
Avaniyapuram Kannan Murugan et al.
CANCER RESEARCH (2011)
Genetic Alterations in Medullary Thyroid Cancer: Diagnostic and Prognostic Markers
A. Taccaliti et al.
CURRENT GENOMICS (2011)
MiR-129-5p is required for histone deacetylase inhibitor-induced cell death in thyroid cancer cells
Patrick Brest et al.
ENDOCRINE-RELATED CANCER (2011)
The mTOR protein as a target in thyroid cancer
Elaine Cristina Lima de Souza et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2011)
Molecular genetics and diagnosis of thyroid cancer
Yuri E. Nikiforov et al.
NATURE REVIEWS ENDOCRINOLOGY (2011)
Tumor-Associated Macrophages (TAMs) Form an Interconnected Cellular Supportive Network in Anaplastic Thyroid Carcinoma
Bernard Caillou et al.
PLOS ONE (2011)
CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction
Xi Wen Zhao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Higher Intratumoral Expression of CD1a, Tryptase, and CD68 in a Follicular Variant of Papillary Thyroid Carcinoma Compared to Adenomas: Correlation with Clinical and Pathological Parameters
Agnese Proietti et al.
THYROID (2011)
Phase II Study of Daily Sunitinib in FDG-PET-Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation
Laurie L. Carr et al.
CLINICAL CANCER RESEARCH (2010)
Tumor-Associated Lymphocytes and Increased FoxP3+ Regulatory T Cell Frequency Correlate with More Aggressive Papillary Thyroid Cancer
Jena D. French et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors
Motoyasu Saji et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2010)
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study
Keith C. Bible et al.
LANCET ONCOLOGY (2010)
Mast cells have a protumorigenic role in human thyroid cancer
R. M. Melillo et al.
ONCOGENE (2010)
Genetic Alterations in the Phosphatidylinositol-3 Kinase/Akt Pathway in Thyroid Cancer
Mingzhao Xing
THYROID (2010)
Increasing Incidence of Differentiated Thyroid Cancer in the United States, 1988-2005
Amy Y. Chen et al.
CANCER (2009)
The BRAFV600E Oncogene Induces Transforming Growth Factor β Secretion Leading to Sodium Iodide Symporter Repression and Increased Malignancy in Thyroid Cancer
Garcilaso Riesco-Eizaguirre et al.
CANCER RESEARCH (2009)
CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
Siddhartha Jaiswal et al.
CELL (2009)
Overcoming resistance to tyrosine kinase inhibitors Lessons learned from cancer cells treated with EGFR antagonists
Brent N. Rexer et al.
CELL CYCLE (2009)
Lack of Therapeutic Effect of the Histone Deacetylase Inhibitor Vorinostat in Patients with Metastatic Radioiodine-Refractory Thyroid Carcinoma
Jennifer A. Woyach et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Effectiveness of retinoic acid treatment for redifferentiation of thyroid cancer in relation to recovery of radioiodine uptake
C. A. Fernandez et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2009)
Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
David S. Cooper et al.
THYROID (2009)
Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer
Mabel Ryder et al.
ENDOCRINE-RELATED CANCER (2008)
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study
Ezra E. W. Cohen et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Thyroid carcinoma: molecular pathways and therapeutic targets
Yuri E. Nikiforov
MODERN PATHOLOGY (2008)
Immunology's foundation: the 100-year anniversary of the Nobel Prize to Paul Ehrlich and Elie Metchnikoff
Stefan H. E. Kaufmann
NATURE IMMUNOLOGY (2008)
Motesanib diphosphate in progressive differentiated thyroid cancer
Steven I. Sherman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma
J. W. B. de Groot et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism
C. Durante et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
P. J. Roberts et al.
ONCOGENE (2007)
Lymphocyte and immature dendritic cell infiltrates in differentiated, poorly differentiated, and undifferentiated thyroid carcinoma
Clara Ugolini et al.
THYROID (2007)
A clinical study of all-trans-retinoid-induced differentiation therapy of advanced thyroid cancer
Yifan Zhang et al.
NUCLEAR MEDICINE COMMUNICATIONS (2007)
Minireview: The paired box-8/peroxisome proliferator-activated receptor-gamma oncogene in thyroid tumorigenesis
Honey V. Reddi et al.
ENDOCRINOLOGY (2007)
Review: Side effects of approved molecular targeted therapies in solid cancers
Christian Widakowich et al.
ONCOLOGIST (2007)
A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer
Electron Kebebew et al.
SURGERY (2006)
The C-terminal CD47/IAP-binding domain of thrombospondin-1 prevents camptothecin- and doxorubicin-induced apoptosis in human thyroid carcinoma cells
G. M. Rath et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2006)
Clinicopathological significance of major histocompatibility complex class I-related chain A and B expression in thyroid cancer
Xiulong Xu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Pathogenetic mechanisms in thyroid follicular-cell neoplasia
T Kondo et al.
NATURE REVIEWS CANCER (2006)
Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation
TJ Giordano et al.
CLINICAL CANCER RESEARCH (2006)
Expression of MAGE tumor-associated antigen in thyroid carcinomas
Marija Milkovic et al.
ENDOCRINE PATHOLOGY (2006)
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer
MZ Xing et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Recovery of NIS expression in thyroid cancer cells by overexpression of Pax8 gene
I Presta et al.
BMC CANCER (2005)
Alterations of the BRAF gene in thyroid tumors
R Ciampi et al.
ENDOCRINE PATHOLOGY (2005)
The PAX8/PPARc fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARc inhibition
JG Powell et al.
ONCOGENE (2004)
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
PTC Wan et al.
CELL (2004)
Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers
H Namba et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Papillary thyroid carcinomas from young adults and children contain a mixture of lymphocytes
J Modi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma -: An unusually high prevalence of ras mutations
ZW Zhu et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2003)
RAS point mutations and PAX8-PPARγ rearrangement in thyroid tumors:: Evidence for distinct molecular pathways in thyroid follicular carcinoma
MN Nikiforova et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
BRAF mutation in papillary thyroid carcinoma
J Cohen et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Genetic and biological subgroups of low-stage follicular thyroid cancer
CA French et al.
AMERICAN JOURNAL OF PATHOLOGY (2003)
BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas
MN Nikiforova et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Cancer immunoediting: from immunosurveillance to tumor escape
GP Dunn et al.
NATURE IMMUNOLOGY (2002)
Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer:: final results of a pilot study
D Simon et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2002)
S-100 protein+ dendritic cells and CD34+ dendritic interstitial cells in thyroid lesions
A Batistatou et al.
ENDOCRINE PATHOLOGY (2002)
RET oncogene activation in papillary thyroid carcinoma
G Tallini et al.
ADVANCES IN ANATOMIC PATHOLOGY (2001)
PAX8-PPARγ1 fusion in oncogene human thyroid carcinoma
TG Kroll et al.
SCIENCE (2000)
Retinoblastoma expression in thyroid neoplasms
F Anwar et al.
MODERN PATHOLOGY (2000)
Papillary carcinoma of the thyroid - Hepatocyte growth factor (HGF) stimulates tumor cells to release chemokines active in recruiting dendritic cells
S Scarpino et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
N-ras mutation in poorly differentiated thyroid carcinomas: Correlation with bone metastases and inverse correlation to thyroglobulin expression
F Basolo et al.
THYROID (2000)